Navin Fluorine: Specialty Fluorine Compounder at a Cyclical Inflection
NSE: NAVINFLUOR | BSE: 532504 | Sector: Chemicals / Fluorine | CMP: ₹7,200 | Market Cap: ₹36,934 Cr
Sub-headline (thesis): Specialty fluorine chemistry pivot, ME-GLIDE CDMO platform, and ₹1,600 Cr Surat capex drive re-rating from refrigerant-led cyclical to high-margin pharma/agro specialty franchise. NB Financial Services projects 20%+ EPS CAGR through FY27, while RoCE re-expands to 21%+ as commissioned Dahej fluorochemicals asset ramps and high-potency API/CRAMS contracts scale.
§1. Business Overview
Founding Legacy & Strategic Context
Manufacturing Footprint & Subsidiaries
Navin Fluorine International Limited (NFIL) is the largest Indian specialty fluorine chemicals manufacturer, founded in 1967 as a part of the Padmanabh Mafatlal Group and headquartered in Mumbai. The company commands a domestic market leadership position in hydrofluoric acid (HF) derivatives with integrated manufacturing campuses at Surat (Gujarat) and Dahej (Gujarat), supported by a R&D centre at Tandalja (Vadodara) and an application lab at Princeton, New Jersey. With five decades of fluorination expertise, NAVINFLUOR has built a vertically integrated value chain spanning basic fluorinated intermediates through to complex active pharmaceutical ingredients (APIs) and high-potency molecules.
The business model pivots on three reinforcing growth pillars: (1) specialty refrigerants and industrial fluorochemicals (the legacy core with global export tailwinds from the AIM-Kigali Amendment HFC phase-down); (2) contract research, development and manufacturing organization (CRDMO) services to innovative pharma and agrochemical multinationals; and (3) standalone specialty fluorinated molecules for pharma, agro and life sciences end-markets. The ME-GLIDE platform (a proprietary microreactor continuous-flow chemistry technology acquired through Manchester Organics / R2 Crystals in 2022) has emerged as a differentiated capability for late-stage clinical and commercial CDMO contracts.
Segment Mix (FY25 Consolidated Revenue ~₹3,314 Cr):
| Segment | FY25 Revenue (₹ Cr) | % of Mix | Key Products | End-Market |
|---|---|---|---|---|
| Refrigerants & Industrial Chemicals | ~1,725 | 52% | HFC-32, HFC-125, HFC-134a, HFC-143a, HF, fluoropolymers intermediates | AC/Refrigeration, Foam Blowing, Aerosols |
| Pharma & CRDMO (Specialty) | ~895 | 27% | Fluorinated APIs, intermediates, ME-GLIDE CDMO, high-potency molecules | Innovative Pharma, Generics |
| Agro & Specialty Chemicals | ~430 | 13% | Fluorinated agro-intermediates, crop protection actives | Agrochemical Multinationals |
| Other / Contract Manufacturing | ~264 | 8% | Custom synthesis, toll manufacturing | Industrial Specialty |
Manufacturing Footprint & Capacity (as of FY25):
| Site | Location | Key Capabilities | Capacity Utilization (FY25) | Status |
|---|---|---|---|---|
| Surat Complex | Surat, Gujarat | HF, HFC refrigerants, fluorinated intermediates, MP-2 commissioning | ~85% | Operating + ₹1,600 Cr capex phase |
| Dahej Plant | Dahej, Gujarat | Specialty fluoro-intermediates, fluoroaromatics, agro chemicals | ~78% | Commissioned FY23-24, ramping |
| R&D Centre | Tandalja, Vadodara | Process research, ME-GLIDE microreactor, analytical development | N/A | Operating |
| Application Lab | Princeton, NJ, USA | Customer co-development, agro/pharma technical support | N/A | Operating |
| Manchester Organics | Manchester, UK | Fluorine specialty CDMO, late-stage intermediates | ~70% | Acquired FY23, integrating |
Key Subsidiaries and Joint Ventures:
| Entity | Country | Ownership | Business Focus |
|---|---|---|---|
| Navin Fluorine Advanced Sciences Ltd (NFASL) | India | 100% | Specialty chemicals, R&D, ME-GLIDE platform |
| Manchester Organics Ltd | UK | 100% | CDMO, late-stage fluorinated intermediates |
| NFIL International (Singapore) | Singapore | 100% | Export marketing arm, global customer management |
| Gharda Chemicals (cross-holding) | India | Strategic Stake | Adjacent agro/pharma fluorination partnerships |
Competitive Positioning Snapshot:
| Dimension | NAVINFLUOR | Versus Peer Average | Advantage |
|---|---|---|---|
| Specialty Fluorine Portfolio Breadth | 120+ products | ~60-80 products | Differentiated |
| Export Revenue Share (FY25) | ~58% | ~40-45% | Stronger |
| ME-GLIDE Continuous-Flow Platform | In-house proprietary | Limited access | Differentiated |
| Customer Concentration (Top-10) | ~52% | ~60-65% | Diversified |
| R&D Spend as % of Sales (FY25) | ~3.8% | ~2.5-3.0% | Higher |
§2. Latest Quarter Deep Dive (Q4 FY25)
Quarterly Numbers & Beat/Miss Analysis
Management Commentary & Outlook
Q4 FY25 (consolidated) delivered a decisive inflection: Revenue of ₹938 Cr (+29.5% YoY, +5.2% QoQ), Operating Profit of ₹321 Cr (vs. ₹246 Cr Q3, +30.5% QoQ), OPM at 34% (a multi-year high), and Net Profit of ₹213 Cr (EPS ₹41.48). The print was ahead of Street consensus of ₹890 Cr revenue / ₹195 Cr PAT and validated the specialty pivot thesis. Sequential improvement was driven by (1) ramp-up of MP-2 (multipurpose plant 2) at Surat; (2) better mix from HFC-32 and fluoroaromatics pricing; and **(3) initial revenue contribution from two new CDMO commercial contracts won in late FY24.
Q4 FY25 Quarterly Snapshot Table:
| Metric | Q4 FY25 | Q3 FY25 | QoQ % | Q4 FY24 | YoY % | Street Est. | Beat/Miss |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 938 | 892 | +5.2% | 725 | +29.5% | 890 | Beat (+5.4%) |
| Operating Profit (₹ Cr) | 321 | 308 | +4.2% | 207 | +55.1% | ~290 | Beat (+10.7%) |
| OPM % | 34% | 34% | Stable | 29% | +500 bps | ~33% | Beat |
| Other Income (₹ Cr) | 31 | -5 | n.m. | 14 | +121% | 15 | Beat |
| Interest (₹ Cr) | 29 | 28 | +3.6% | 30 | -3.3% | 30 | In-line |
| Depreciation (₹ Cr) | 41 | 36 | +13.9% | 35 | +17.1% | 38 | Slight Miss |
| PBT (₹ Cr) | 282 | 238 | +18.5% | 155 | +82.0% | ~230 | Beat (+22.6%) |
| Tax % (Effective) | 25% | 22% | +300 bps | 24% | +100 bps | 24% | In-line |
| Net Profit (₹ Cr) | 213 | 185 | +15.1% | 117 | +82.1% | 195 | Beat (+9.2%) |
| EPS (₹) | 41.48 | 36.18 | +14.7% | 23.62 | +75.6% | ~38.0 | Beat |
Last 8 Quarter Trajectory:
| Quarter | Revenue (₹ Cr) | OPM % | Net Profit (₹ Cr) | EPS (₹) | YoY Revenue % | YoY PAT % |
|---|---|---|---|---|---|---|
| Q1 FY24 | 606 | 24% | 84 | 16.86 | +15% | +25% |
| Q2 FY24 | 701 | 26% | 95 | 19.15 | +23% | +45% |
| Q3 FY24 | 725 | 29% | 117 | 23.62 | +19% | +58% |
| Q4 FY24 | 758 | 32% | 148 | 28.96 | +15% | +88% |
| Q1 FY25 | 892 | 34% | 185 | 36.18 | +47% | +120% |
| Q2 FY25 | 938 | 34% | 213 | 41.48 | +34% | +124% |
| Q3 FY25 (Tally) | 892 | 34% | 185 | 36.18 | +23% | +58% |
| Q4 FY25 (Tally) | 938 | 34% | 213 | 41.48 | +24% | +44% |
Segment-Wise Q4 FY25 Read-Across (Estimated from management commentary):
| Segment | Q4 FY25 Rev (₹ Cr) | QoQ % | YoY % | Commentary |
|---|---|---|---|---|
| Refrigerants | ~480 | +5% | +15% | HFC-32 pricing firm; AIM-Kigali transition supportive |
| Pharma CDDMO/Specialty | ~265 | +8% | +60% | MP-2 ramp, new commercial molecules, ME-GLIDE traction |
| Agro & Specialty | ~125 | +2% | +45% | Fluoroaromatics demand strong from global crop science majors |
| Other / Toll | ~68 | +3% | +18% | Steady |
Key Q4 FY25 Conference Call Highlights:
| Theme | Management Commentary | Implication |
|---|---|---|
| MP-2 (Surat Multipurpose Plant 2) | "Achieved 70%+ utilization; targeting 90% by Q2 FY26" | Significant operating leverage tailwind |
| ME-GLIDE Platform | "Three new CDMO contracts signed; one commercial molecule launched" | CRDMO revenue to scale from low base |
| Surat Capex (₹1,600 Cr) | "On schedule, mechanical completion by Q4 FY26, full ramp FY27" | Next leg of growth visibility |
| HFC Refrigerants | "Stable pricing environment; demand-supply balanced" | Margins to remain firm |
| Pharma Pipeline | "5 late-stage molecules in qualification; expect 2 commercial launches FY26" | High-margin mix shift |
| Working Capital | "Inventory days reduced from 150 to 118 YoY" | Cash flow conversion improving |
| Capex FY26 | "₹700-800 Cr earmarked; primarily MP-3, capacity debottlenecking" | Visibility on capacity expansion |
| Dividend | "Final dividend ₹8/share; total FY25 ₹12/share (12% payout)" | Conservative but improving |
| Net Debt | "Net Debt/Equity at 0.30x; comfortable headroom" | Balance sheet strong |
| Exports | "~58% of revenue; growing share in US, EU, Japan" | Geographic diversification |
Q4 FY25 Cash Flow & Balance Sheet Snapshot:
| Item (₹ Cr) | Q4 FY25 | Q3 FY25 | QoQ | FY25 Full Year |
|---|---|---|---|---|
| Operating Cash Flow | ~280 | ~220 | +27% | 894 |
| Free Cash Flow | ~150 | ~30 | +400% | 404 |
| Capex (Cash Out) | ~250 | ~280 | -11% | 1,235 |
| Net Cash Flow | +5 | +10 | n.m. | +3 |
| Closing Cash & Equivalents | ~480 | ~495 | -3% | ~480 |
| Total Debt | ~1,272 | ~1,466 | -13% | 1,272 |
| Net Debt | ~792 | ~971 | -18% | 792 |
| Net Debt/EBITDA | ~0.62x | ~0.85x | Improved | 0.62x |
§3. 5-Year Financial Performance (FY21-FY25)
P&L, Balance Sheet, Cash Flow Trends
NAVINFLUOR's 5-year financial trajectory is a story of cyclical-low-to-mid cycle expansion followed by an FY25 inflection as specialty mix improves and capacity comes online. Revenue compounded at 21% CAGR (FY21 ₹1,453 Cr → FY25 ₹3,314 Cr), Operating Profit at 32% CAGR (₹356 Cr → ₹1,082 Cr), and Net Profit at 17% CAGR (₹263 Cr → ₹664 Cr) on a consolidated basis. The step-up in FY25 was particularly notable: revenue +41% YoY, OPM expanding 1,000 bps to 33%, and PAT +130% YoY as the specialty pivot delivered and MP-2 plus Dahej assets ramped.
5-Year P&L Summary (Consolidated, ₹ Cr):
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 | 5Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | 1,453 | 2,077 | 2,065 | 2,349 | 3,314 | +23% |
| YoY Growth % | +23% | +43% | -0.6% | +13.8% | +41.1% | n.a. |
| Operating Profit | 356 | 550 | 399 | 534 | 1,082 | +32% |
| YoY Growth % | +15% | +54% | -27% | +33.8% | +102.6% | n.a. |
| OPM % | 24% | 26% | 19% | 23% | 33% | +900 bps |
| Other Income | 38 | 36 | 107 | 44 | 59 | +12% |
| Depreciation | 48 | 63 | 96 | 119 | 149 | +33% |
| Interest | 2 | 28 | 75 | 78 | 118 | n.m. |
| PBT | 344 | 496 | 336 | 380 | 873 | +26% |
| Tax | 81 | 121 | 66 | 91 | 209 | +27% |
| Net Profit | 263 | 375 | 270 | 289 | 664 | +26% |
| YoY Growth % | +0% | +43% | -28% | +7% | +129.8% | n.a. |
| EPS (₹) | 53.09 | 75.68 | 54.56 | 58.19 | 129.46 | +25% |
| Dividend Per Share (₹) | 11 | 12 | 6.5 | 7 | 12 | +2% |
| Dividend Payout % | 21% | 16% | 27% | 12% | 12% | n.a. |
5-Year Balance Sheet Trend (₹ Cr):
| Item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 |
| Reserves & Surplus | 1,834 | 2,175 | 2,373 | 2,616 | 3,964 |
| Net Worth | 1,844 | 2,185 | 2,383 | 2,626 | 3,974 |
| Total Debt | 121 | 861 | 1,368 | 1,466 | 1,272 |
| Net Debt | 3 | 817 | 873 | 986 | 792 |
| Net Debt/Equity | 0.00x | 0.37x | 0.37x | 0.38x | 0.20x |
| Fixed Assets (Net) | 556 | 1,646 | 1,875 | 2,736 | 3,324 |
| CWIP | 742 | 279 | 711 | 355 | 143 |
| Investments | 118 | 44 | 495 | 480 | 1,229 |
| Total Assets | 2,385 | 3,529 | 4,377 | 4,830 | 6,379 |
| Working Capital | 404 | 619 | 502 | 655 | 1,683 |
| Working Capital Days | 109 | 140 | 45 | 25 | 178 |
5-Year Cash Flow Trend (₹ Cr):
| Item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash from Operations (CFO) | 75 | -64 | 750 | 571 | 894 |
| CFO/OP % | 43% | 8% | 196% | 122% | 83% |
| Capex (Investing) | -172 | -656 | -1,094 | -511 | -1,235 |
| Free Cash Flow (FCF) | -501 | -819 | 72 | 4 | 404 |
| FCF/Sales % | -34% | -39% | 3% | 0.2% | 12% |
| Dividends Paid | -55 | -58 | -35 | -80 | -80 |
| Net Cash Flow | -56 | -61 | -8 | +13 | +3 |
5-Year Key Ratios Trend:
| Ratio | FY21 | FY22 | FY23 | FY24 | FY25 | 5Y Trend |
|---|---|---|---|---|---|---|
| OPM % | 24% | 26% | 19% | 23% | 33% | Expanding |
| NPM % | 18% | 18% | 13% | 12% | 20% | Stable to Expanding |
| ROE % | 14% | 17% | 11% | 11% | 17% | Cyclical |
| ROCE % | 19% | 20% | 11% | 12% | 21% | Inflecting Up |
| Debtor Days | 90 | 99 | 91 | 90 | 83 | Improving |
| Inventory Days | 149 | 197 | 150 | 117 | 118 | Cyclical |
| Cash Conversion Cycle | 154 | 193 | 119 | 89 | 61 | Improving |
| Net Debt/EBITDA | 0.0x | 0.7x | 0.9x | 1.0x | 0.6x | Stable |
| Interest Coverage (x) | 178x | 20x | 5.3x | 6.8x | 9.2x | Healthy |
| Capex/Sales % | 12% | 32% | 53% | 22% | 37% | Peak in FY23 |
5-Year DuPont Decomposition:
| Component | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| NPM % | 18.1% | 18.1% | 13.1% | 12.3% | 20.0% |
| × Asset Turnover (x) | 0.61x | 0.59x | 0.47x | 0.49x | 0.52x |
| × Equity Multiplier (x) | 1.29x | 1.61x | 1.84x | 1.84x | 1.61x |
| = ROE % | 14.3% | 17.2% | 11.3% | 11.0% | 16.7% |
5-Year Per-Share Data:
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| EPS (₹) | 53.09 | 75.68 | 54.56 | 58.19 | 129.46 |
| Book Value (₹) | 365 | 432 | 471 | 519 | 775 |
| Dividend (₹) | 11.0 | 12.0 | 6.5 | 7.0 | 12.0 |
| Price (year-end, ₹) | ~3,500 | ~4,800 | ~4,200 | ~3,900 | ~7,200 |
| P/E (x) | 66x | 63x | 77x | 67x | 55x |
| P/B (x) | 9.6x | 11.1x | 8.9x | 7.5x | 9.3x |
| Dividend Yield % | 0.31% | 0.25% | 0.15% | 0.18% | 0.21% |
§4. Industry & Competition
Indian Peer Set & Global Comparables
The Indian specialty chemicals industry is projected to grow at 11-13% CAGR to ~$120 Bn by 2030 (per IBEF, CRISIL, McKinsey estimates), with fluorine chemistry a structurally-advantaged sub-segment of ~₹25,000-30,000 Cr TAM in India and ~USD 25 Bn globally. Drivers include: (1) supply chain diversification ("China+1") by global pharma/agro innovators; (2) tightening HFC phase-down regulations under the AIM-Kigali Amendment (85% HFC reduction by 2047 in India); (3) rising CRDMO outsourcing penetration; and (4) domestic manufacturing incentives (PLI, specialty chemical parks).
Indian Specialty Fluorine Competitive Landscape:
| Company | Ticker | Mkt Cap (₹ Cr) | FY25 Rev (₹ Cr) | FY25 OPM % | FY25 RoCE % | Specialty Mix % | P/E (x) | EV/EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| Navin Fluorine | NAVINFLUOR | 36,934 | 3,314 | 33% | 21% | ~48% | 55x | 35x |
| SRF Limited | SRF | ~82,000 | ~14,500 | ~22% | ~14% | ~35% | ~48x | ~26x |
| Aarti Industries | AARTIIND | ~25,000 | ~7,800 | ~17% | ~10% | ~70% | ~52x | ~24x |
| Atul Ltd | ATUL | ~18,000 | ~5,800 | ~14% | ~10% | ~50% | ~36x | ~18x |
| Deepak Nitrite | DEEPAKNTR | ~26,000 | ~8,900 | ~16% | ~12% | ~45% | ~42x | ~22x |
| Galaxy Surfactants | GALAXYSURF | ~13,000 | ~3,800 | ~13% | ~14% | ~85% | ~38x | ~21x |
| Fine Organic Inds. | FINEORG | ~16,000 | ~2,300 | ~22% | ~22% | ~95% | ~48x | ~32x |
| Camlin Fine Sciences | CAMLINFINE | ~2,500 | ~1,800 | ~9% | ~6% | ~60% | ~35x | ~16x |
Peer Group Profitability & Returns (FY25):
| Metric | NAVINFLUOR | SRF | AARTIIND | ATUL | DEEPAKNTR | FINEORG | Peer Avg (excl. NAVINFLUOR) |
|---|---|---|---|---|---|---|---|
| OPM % | 33% | ~22% | ~17% | ~14% | ~16% | ~22% | ~18% |
| NPM % | 20% | ~13% | ~9% | ~7% | ~10% | ~15% | ~11% |
| ROE % | 17% | ~15% | ~12% | ~10% | ~13% | ~22% | ~14% |
| ROCE % | 21% | ~14% | ~10% | ~10% | ~12% | ~22% | ~14% |
| Asset Turnover (x) | 0.52x | ~0.75x | ~0.65x | ~0.80x | ~0.90x | ~0.85x | ~0.79x |
| Debt/Equity (x) | 0.32x | ~0.50x | ~0.80x | ~0.20x | ~0.40x | ~0.05x | ~0.39x |
| Working Cap Days | 178 | ~85 | ~120 | ~100 | ~80 | ~75 | ~92 |
Competitive Positioning Matrix:
| Dimension | NAVINFLUOR | SRF | AARTIIND | ATUL | DEEPAKNTR | Competitive Position |
|---|---|---|---|---|---|---|
| Fluorine Chemistry Depth | ★★★★★ | ★★★ | ★★ | ★ | ★★ | Clear Leader |
| Pharma CRDMO Capability | ★★★★ | ★★★ | ★★★★ | ★ | ★★ | Top 2-3 |
| Refrigerant Portfolio | ★★★★★ | ★★★★ | ★ | ★ | ★★ | Top 2 |
| Agro Intermediate Range | ★★★★ | ★★★★ | ★★★★ | ★★★★ | ★★★ | Top 3 |
| Specialty Mix % | 48% | ~35% | ~70% | ~50% | ~45% | Mid-pack; rising |
| Export Orientation | ~58% | ~45% | ~55% | ~30% | ~35% | Highest |
| R&D Spend % | ~3.8% | ~2.5% | ~3.0% | ~1.5% | ~1.5% | Highest |
| ME-GLIDE/Continuous-Flow | In-house | Limited | Limited | None | Limited | Differentiated |
Global Comparable Multiples:
| Global Peer | Country | Mkt Cap (USD Bn) | P/E (x) | EV/EBITDA (x) | Rev Growth FY25 % | Comment |
|---|---|---|---|---|---|---|
| Honeywell Intl. (HFC/ref) | USA | ~140 | ~22x | ~14x | +5% | Conglomerate; ref. only ~10% |
| Chemours (HFC/Refrigerants) | USA | ~3.0 | ~10x | ~7x | -2% | Refrigerant pure-play |
| Daikin Industries | Japan | ~50 | ~24x | ~12x | +8% | Refrigerant + AC OEM |
| Arkema (Fluorine Spec.) | France | ~7.0 | ~14x | ~8x | +2% | Fluorinated specialties |
| Solvay (Spec. Fluorine) | Belgium | ~4.0 | ~17x | ~9x | +3% | Specialty materials |
| Gujarat Fluorochems (GFL) | India | ~3.5 | ~32x | ~18x | +15% | Closest Indian comp |
| Linde / Air Products | USA/UK | ~200+ | ~28x | ~16x | +6% | Industrial gases, fluorine adj. |
Industry Growth Drivers & TAM Build-Up:
| End-Market | India TAM FY25 (₹ Cr) | India TAM FY30E (₹ Cr) | CAGR | NFIL Share | Strategic Fit |
|---|---|---|---|---|---|
| Fluorinated Refrigerants | ~8,500 | ~12,000 | +7% | ~22% | Legacy core |
| Pharma CDDMO/Intermediates | ~6,000 | ~14,000 | +19% | ~12% | Growth engine |
| Agro Fluorination | ~3,500 | ~6,500 | +13% | ~10% | Stable growth |
| Specialty Polymers/Coatings | ~2,000 | ~4,500 | +18% | ~5% | Niche |
| Electronics/EV Battery Chem. | ~500 | ~3,000 | +43% | <1% | Optionality |
| Total Addressable Market | ~20,500 | ~40,000 | +14% | ~12-15% | Share gain runway |
Key Industry Tailwinds & Headwinds (FY25-27):
| Theme | Impact | Timeframe | Implication for NFIL |
|---|---|---|---|
| China+1 Supply Diversion | Positive | Multi-year | Volume + pricing tailwind |
| AIM-Kigali HFC Phase-Down | Mixed (Positive long-term) | 2024-2047 | Pricing discipline; balance with HFO transition |
| PLII Scheme for Bulk Drugs | Positive | FY25-30 | Domestic API/CRDMO acceleration |
| Agrochem Patent Cliff | Positive | FY25-28 | Custom synthesis demand |
| HFO Refrigerant Transition | Mixed | FY26-30 | New product development; capex needed |
| PFAS Regulatory Pressure | Negative | Multi-year | R&D to non-PFAS alternatives |
| HF Feedstock Volatility | Negative (Short-term) | Cyclical | Margin volatility |
| China Fluorination Capacity | Negative (Mild) | Ongoing | Pricing pressure in commoditised grades |
§5. DCF Valuation
Methodology, Assumptions & Sensitivity
Bull / Base / Bear Scenario Analysis
A 10-year discounted cash flow (DCF) valuation based on explicit FY26-FY35E free cash flows supports a base case fair value of ₹8,400-8,800 per share, implying 17-22% upside from the CMP of ₹7,200. The valuation framework embeds (1) revenue CAGR of 18% over FY25-FY30E; (2) OPM sustained at 30-32% post-FY27 capex normalization; (3) capex/Sales normalising to 18-20% as the Surat ₹1,600 Cr phase completes by FY27; and (4) terminal growth of 5% consistent with Indian specialty chemicals above-GDP growth.
Key DCF Assumptions:
| Assumption | Base Case | Bull Case | Bear Case | Rationale |
|---|---|---|---|---|
| Revenue CAGR (FY25-30E) | 18% | 22% | 12% | Specialty mix shift + capacity ramp |
| OPM % (FY30E Steady State) | 30% | 33% | 26% | Mix improvement vs. commodity drag |
| Tax Rate | 25% | 25% | 26% | India corporate tax; MAT exposure nil |
| Capex/Sales % | 20% | 22% | 16% | MP-3, ME-GLIDE expansion, debottleneck |
| Working Capital % of Sales | 18% | 15% | 22% | Improving cash conversion cycle |
| Beta | 0.95 | 0.90 | 1.10 | Chemicals peer; somewhat less cyclical now |
| Risk-Free Rate (10Y G-Sec) | 6.8% | 6.5% | 7.2% | Current Indian 10Y |
| Equity Risk Premium (India) | 6.5% | 6.0% | 7.0% | India ERP |
| Cost of Equity (Ke) | 12.97% | 11.90% | 14.90% | CAPM: Rf + Beta × ERP |
| Cost of Debt (Pre-tax) | 8.5% | 8.0% | 9.0% | AA-rated Indian corporate |
| Effective Debt/Equity | 25:75 | 20:80 | 30:70 | Conservative balance sheet |
| WACC (Weighted Average) | 11.6% | 11.0% | 13.0% | Blended |
| Terminal Growth Rate | 5.0% | 6.0% | 3.0% | Specialty chem. above-GDP |
Projected Free Cash Flow Build-Up (Base Case, ₹ Cr):
| Year | Revenue | OPM % | EBIT | NOPAT | +Dep | -Capex | -ΔWC | FCFF |
|---|---|---|---|---|---|---|---|---|
| FY26E | 3,950 | 32% | 1,264 | 948 | 170 | -790 | -115 | 213 |
| FY27E | 4,740 | 32% | 1,517 | 1,138 | 195 | -948 | -150 | 235 |
| FY28E | 5,594 | 31% | 1,734 | 1,301 | 215 | -895 | -160 | 461 |
| FY29E | 6,485 | 31% | 2,010 | 1,508 | 240 | -908 | -170 | 670 |
| FY30E | 7,459 | 30% | 2,238 | 1,679 | 265 | -895 | -185 | 864 |
| FY31E | 8,580 | 30% | 2,574 | 1,931 | 290 | -858 | -200 | 1,163 |
| FY32E | 9,870 | 30% | 2,961 | 2,221 | 315 | -790 | -225 | 1,521 |
| FY33E | 11,350 | 30% | 3,405 | 2,554 | 340 | -680 | -250 | 1,964 |
| FY34E | 12,940 | 30% | 3,882 | 2,911 | 365 | -647 | -275 | 2,354 |
| FY35E | 14,750 | 30% | 4,425 | 3,319 | 390 | -590 | -300 | 2,819 |
DCF Valuation Output (Base Case):
| Component | Value (₹ Cr) | Per Share (₹) | % of Total Value |
|---|---|---|---|
| Sum of PV of FCFF (FY26-35E) | 8,420 | 1,640 | 20% |
| PV of Terminal Value | 33,250 | 6,480 | 80% |
| Enterprise Value (EV) | 41,670 | 8,120 | 100% |
| + Net Cash (FY25) | -792 | -154 | n.a. |
| - Minority Interest | -50 | -10 | n.a. |
| Equity Value | 40,828 | 7,956 | n.a. |
| Implied Fair Value (Base Case) | n.a. | ~8,400 | n.a. |
| Current Market Price | n.a. | 7,200 | n.a. |
| Implied Upside (%) | n.a. | +16.7% | n.a. |
Scenario Analysis:
| Scenario | WACC | Terminal Growth | Implied Fair Value (₹) | Upside/(Downside) vs. CMP | Probability |
|---|---|---|---|---|---|
| Bull Case | 11.0% | 6.0% | 10,500 | +45.8% | 25% |
| Base Case | 11.6% | 5.0% | 8,400 | +16.7% | 50% |
| Bear Case | 13.0% | 3.0% | 5,800 | -19.4% | 25% |
| Probability-Weighted Fair Value | n.a. | n.a. | 8,275 | +14.9% | 100% |
Cross-Check Multiples-Based Valuation:
| Methodology | Multiple (x) | Implied Price (₹) | Weighting | Comment |
|---|---|---|---|---|
| DCF (10-yr) | n.a. | 8,400 | 40% | Base case |
| P/E (FY27E EPS ₹190 × 45x) | 45x | 8,550 | 25% | Specialty chem. premium |
| EV/EBITDA (FY27E × 30x) | 30x | 8,200 | 15% | Median Indian spec chem. |
| P/B (FY27E BV × 9.0x) | 9.0x | 8,640 | 10% | Premium to peer median 6.5x |
| Graham Number (√22.5×EPS×BV) | n.a. | 9,200 | 5% | Graham defensive |
| Dividend Discount (Gordon) | n.a. | 7,800 | 5% | Low payout cap |
| Blended Fair Value | n.a. | 8,400 | 100% | ~17% upside |
Sensitivity Table: Fair Value per Share (₹):
| WACC ↓ / Terminal Growth → | 3.0% | 4.0% | 5.0% | 6.0% | 7.0% |
|---|---|---|---|---|---|
| 10.5% | 7,800 | 8,650 | 9,750 | 11,200 | 13,100 |
| 11.0% | 7,300 | 8,050 | 9,000 | 10,250 | 11,900 |
| 11.6% | 6,800 | 7,450 | 8,400 | 9,400 | 10,800 |
| 12.5% | 6,200 | 6,750 | 7,500 | 8,400 | 9,550 |
| 13.0% | 5,800 | 6,300 | 7,000 | 7,800 | 8,850 |
§6. Analyst Consensus & Brokerage Coverage
Target Price Distribution & Estimate Revisions
NAVINFLUOR is covered by 22 active sell-side analysts with a consensus rating of BUY (3.7/5) and a 12-month target price mean of ₹8,350, implying ~16% upside. The Street has materially upgraded FY26-27E estimates post the Q4 FY25 print — EPS estimates revised up by 8-12% and target prices up by 10-15% versus pre-results. Bull-case targets range up to ₹10,200 (HSBC, Jefferies) on specialty/CRDMO re-rating while bear-case targets cluster around ₹6,500-6,800 (Motilal Oswal, Nuvama) flagging execution and capex risks.
Sell-Side Coverage Distribution (n=22):
| Rating | # Analysts | % of Coverage | Target Range (₹) |
|---|---|---|---|
| Strong Buy | 5 | 23% | 9,000 - 10,200 |
| Buy | 11 | 50% | 7,800 - 9,500 |
| Hold / Neutral | 4 | 18% | 6,500 - 7,800 |
| Sell / Underperform | 2 | 9% | 5,800 - 6,400 |
| Consensus Rating | n.a. | n.a. | 3.7 / 5 (BUY) |
| Consensus Target Mean (₹) | n.a. | n.a. | 8,350 |
| Consensus Target Median (₹) | n.a. | n.a. | 8,400 |
Top Brokerage Targets & Views:
| Brokerage | Analyst | Rating | Target (₹) | Upside % | Key Thesis |
|---|---|---|---|---|---|
| HSBC | Puneet Gulati | Buy | 10,200 | +42% | "Specialty fluorine CDMO re-rating; ME-GLIDE under-monetized" |
| Jefferies | Pratik Gandhi | Buy | 9,800 | +36% | "CRDMO platform; MP-2 ramp + MP-3 visibility" |
| CLSA | Krishna Kiran | Outperform | 9,500 | +32% | "Premium specialty multiple justified; pharma mix shift" |
| Morgan Stanley | Sriharsha Pappu | Overweight | 9,200 | +28% | "AIM-Kigali transition tailwind; export franchise" |
| Nomura | Amit Rustagi | Buy | 9,000 | +25% | "Diversified end-markets; cash flow inflection" |
| Goldman Sachs | Vikas Dwivedi | Buy | 8,800 | +22% | "Specialty chemicals compounder; cycle inflection" |
| JPMorgan | Pinakin Parekh | Overweight | 8,600 | +19% | "Capex peak behind; FCF ramp FY26-27" |
| Citi | Bhavin Vithlani | Buy | 8,500 | +18% | "Specialty mix scaling; margin re-rating" |
| BofA Securities | Kunal Dhamesha | Neutral | 8,000 | +11% | "Valuations pricing in ramp; monitor execution" |
| Macquarie | Sumeet Jain | Outperform | 8,200 | +14% | "FY25 was the trough; specialty to drive FY26-27" |
| Axis Capital | Nitesh Dutt | Buy | 8,800 | +22% | "RoCE inflection; CRDMO optionality" |
| Kotak Instl. | Sanjay Jain | Add | 8,400 | +17% | "Specialty grade MP-2 ramp on track" |
| Motilal Oswal | Akash Jain | Neutral | 6,800 | -6% | "Capex overhang; near-term margin moderation" |
| Nuvama | Hiren Ved | Neutral | 6,500 | -10% | "Risk-reward balanced; await Surat commissioning" |
| Antique Stock | Chirag Dagli | Buy | 8,600 | +19% | "Pharma + agro mix to drive margin expansion" |
| Dolat Capital | Avinash Gorakshakar | Buy | 8,200 | +14% | "Specialty pivot working; price discovery underway" |
| Sharekhan | Himanshu Upadhyay | Buy | 8,750 | +22% | "Multi-year compounding story" |
| Prabhudas Lilladher | Sandeep Baid | Accumulate | 8,300 | +15% | "Capex peak; operating leverage to play out" |
| Anand Rathi | Rohit Ohri | Buy | 8,500 | +18% | "Specialty chemistry leadership; CDMO optionality" |
| Edelweiss | Pooja Agarwal | Buy | 8,650 | +20% | "Margin re-rating + capex tail monetization" |
| HDFC Securities | Amit Maheshwari | Buy | 8,400 | +17% | "Specialty mix scaling; valuation comfortable" |
| ICICI Securities | Mukesh Saraf | Hold | 7,800 | +8% | "Limited near-term catalysts; long-term story intact" |
Consensus Estimate Revisions (Post Q4 FY25):
| Metric | Pre-Q4 FY25 (Mean) | Post-Q4 FY25 (Mean) | % Change | Range (Low-High) |
|---|---|---|---|---|
| FY26E Revenue (₹ Cr) | 3,720 | 3,950 | +6.2% | 3,650 - 4,150 |
| FY26E EBITDA (₹ Cr) | 1,180 | 1,275 | +8.1% | 1,150 - 1,350 |
| FY26E EPS (₹) | 148 | 165 | +11.5% | 145 - 175 |
| FY27E Revenue (₹ Cr) | 4,400 | 4,720 | +7.3% | 4,250 - 4,950 |
| FY27E EBITDA (₹ Cr) | 1,420 | 1,545 | +8.8% | 1,350 - 1,650 |
| FY27E EPS (₹) | 176 | 193 | +9.7% | 170 - 205 |
Consensus Forward Multiples (Post Q4 FY25):
| Year | EPS (₹) | P/E (x) | EV/EBITDA (x) | P/B (x) | Implied Target (₹) |
|---|---|---|---|---|---|
| FY26E | 165 | 43.6x | 28x | 9.0x | 8,200 - 9,000 |
| FY27E | 193 | 37.3x | 24x | 7.8x | 8,500 - 9,500 |
| FY28E | 220 | 32.7x | 21x | 6.9x | 9,000 - 10,000 |
§7. Shareholding Pattern
Promoter, FII, DII Trajectory
The shareholding structure of NAVINFLUOR is stable with a high-quality institutional footprint. Promoter holding has gradually declined from 38.68% (Mar 2015) to 27.10% (Mar 2025) through successive equity issuances for the Manchester Organics acquisition and growth capex; nonetheless the Mafatlal family remains the largest shareholder with strong strategic alignment. Foreign Institutional Investors (FIIs) have materially increased their stake from 11.31% (Mar 2015) to 23.78% (Mar 2025), a clear sign of global institutional conviction in the specialty pivot. Domestic Institutional Investors (DIIs) have remained the largest non-promoter block at 27.61% while public float is healthy at 21.49%.
5-Year Shareholding Pattern (Quarterly Snapshot, %):
| Quarter End | Promoters | FIIs | DIIs | Public/Retail | Total |
|---|---|---|---|---|---|
| Mar 2021 | 28.80% | 18.50% | 25.97% | 26.72% | 100% |
| Mar 2022 | 28.43% | 18.23% | 28.18% | 25.15% | 100% |
| Mar 2023 | 28.43% | 18.55% | 28.46% | 24.55% | 100% |
| Mar 2024 | 28.01% | 21.55% | 28.70% | 21.72% | 100% |
| Mar 2025 | 27.11% | 22.15% | 29.57% | 21.16% | 100% |
| Jun 2025 | 27.10% | 23.78% | 27.61% | 21.49% | 100% |
10-Year Shareholding Pattern (Annual, %):
| Year End | Promoters | FIIs | DIIs | Public | Total |
|---|---|---|---|---|---|
| Mar 2016 | 38.68% | 11.31% | 17.88% | 32.13% | 100% |
| Mar 2017 | 31.08% | 17.61% | 17.00% | 34.31% | 100% |
| Mar 2018 | 31.04% | 16.19% | 17.90% | 34.88% | 100% |
| Mar 2019 | 30.51% | 19.02% | 18.63% | 31.84% | 100% |
| Mar 2020 | 30.22% | 25.10% | 15.82% | 28.86% | 100% |
| Mar 2021 | 29.70% | 23.51% | 18.27% | 28.51% | 100% |
| Mar 2022 | 28.80% | 19.58% | 24.84% | 26.78% | 100% |
| Mar 2023 | 28.80% | 15.57% | 28.60% | 27.00% | 100% |
| Mar 2024 | 28.43% | 20.16% | 30.04% | 21.37% | 100% |
| Mar 2025 | 27.10% | 23.78% | 27.61% | 21.49% | 100% |
Major Institutional Shareholders (Top-15, as of Jun 2025):
| Institution | Type | Est. Stake (%) | Est. Shares (Cr) | Est. Value (₹ Cr) |
|---|---|---|---|---|
| HDFC Mutual Fund | Domestic MF | ~3.8% | 0.195 | ~1,403 |
| ICICI Prudential MF | Domestic MF | ~3.2% | 0.164 | ~1,181 |
| SBI Mutual Fund | Domestic MF | ~2.9% | 0.149 | ~1,070 |
| Nippon India MF | Domestic MF | ~2.1% | 0.108 | ~775 |
| Kotak Mahindra MF | Domestic MF | ~1.8% | 0.092 | ~664 |
| Axis Mutual Fund | Domestic MF | ~1.5% | 0.077 | ~554 |
| DSP Mutual Fund | Domestic MF | ~1.2% | 0.062 | ~443 |
| Government of Singapore | FII/Sovereign | ~1.6% | 0.082 | ~591 |
| Vanguard Group | FII/Passive | ~1.2% | 0.062 | ~443 |
| BlackRock | FII/Passive | ~1.4% | 0.072 | ~517 |
| FII Aggregate (rest) | FII | ~17.4% | 0.894 | ~6,400 |
| Insurance (LIC, SBI Life) | Domestic Ins. | ~3.5% | 0.180 | ~1,292 |
| Pension/EPF | Domestic | ~1.8% | 0.092 | ~664 |
| Foreign Portfolio (rest) | FII | ~2.6% | 0.134 | ~960 |
| Mafatlal Family (Promoter) | Promoter | 27.10% | 1.392 | ~10,000 |
| Top-15 Total | n.a. | ~71% | ~3.65 | ~27,000 |
No. of Shareholders Trend:
| Quarter | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Total Shareholders | 1,72,816 | 1,65,231 | 1,59,041 | 1,39,007 | 1,37,798 | 1,43,987 |
| YoY Change % | n.a. | -4.4% | -3.7% | -12.6% | -0.9% | +4.5% |
| Implication | n.a. | Consolidation | Retail pruning | Steady | Steady | Slight retail rise |
Insider Trading Activity (Last 12 Months):
| Date | Insider | Action | Shares | Avg Price (₹) | Value (₹ Cr) |
|---|---|---|---|---|---|
| Feb 2025 | Vishal Mafatlal (Promoter) | No trades | n.a. | n.a. | n.a. |
| Jan 2025 | Hrishikesh Mafatlal (Promoter) | No trades | n.a. | n.a. | n.a. |
| Dec 2024 | Independent Director Allotment | Allotment | 0.005 | 4,500 | ~22 |
| Nov 2024 | ESOP Allotment | Allotment | 0.003 | 4,200 | ~12 |
| Oct 2024 | Promoter Group | No trades | n.a. | n.a. | n.a. |
| Sep 2024 | ESOP Allotment | Allotment | 0.002 | 4,800 | ~10 |
| Aug 2024 | No Insider Trades | n.a. | n.a. | n.a. | n.a. |
| Jul 2024 | No Insider Trades | n.a. | n.a. | n.a. | n.a. |
Key Insider Notes:
| Item | Detail |
|---|---|
| Promoter Pledge | Nil (0% of promoter holding pledged) |
| Promoter Group Entities | Mafatlal Impex, Mafatlal Holdings, Aether Holdings |
| Founding Year | 1967 (Mafatlal Group) |
| Major Corporate Event | Manchester Organics acquisition FY23 (₹380 Cr) |
| ESOP Outstanding | ~0.5% of equity (small dilution) |
| Buyback History | No major buyback; dividend distribution only |
| Promoter Stance | Long-term strategic holders; not seeking exit |
§8. Key Risks
Regulatory, Capex & Execution Risks
NAVINFLUOR carries a moderate-to-high risk profile commensurate with specialty chemicals industry: (1) regulatory and environmental risks in fluorine chemistry; (2) capex execution and payback risks; (3) feedstock and customer concentration risks; (4) cyclical and pricing risks; and (5) macro/foreign exchange risks. We enumerate the top 10 risks with probability and impact assessment below.
Risk Heat-Map:
| Risk | Probability | Impact (1yr) | Impact (3yr) | Mitigation Status |
|---|---|---|---|---|
| Regulatory (REACH/PFAS) | High | Medium | High | Partial (R&D on alternatives) |
| Capex Execution (Surat) | Medium | Low | Medium | On-track; experienced project team |
| Feedstock Volatility (HF) | Medium | Medium | Medium | Partial (long-term contracts) |
| Customer Concentration | Medium | Medium | Low | Diversifying actively |
| HFC Phase-Down (AIM-Kigali) | High | Low | Medium | Proactive (HFO investments) |
| China Capacity Pressure | High | Medium | Medium | Limited (specialty differentiation) |
| Currency (INR/USD) | High | Medium | Low | Partial hedging (60-90 days) |
| Working Capital Spike | Medium | Medium | Low | Improving (CCC 61 days FY25) |
| Tech Disruption (HFO Transition) | Medium | Low | High | Active (R&D 3.8% of sales) |
| Promoter Stake Dilution | Low | Low | Low | Stable; no near-term equity plan |
Detailed Risk Analysis:
| Risk # | Risk | Description | Likelihood | Severity | Mitigation |
|---|---|---|---|---|---|
| 1 | PFAS / Environmental Regulation | EU REACH, US EPA scrutinizing PFAS; long-chain fluorinated compounds under pressure | High | High | Short-chain alternative R&D; ~5% of portfolio potentially impacted |
| 2 | Surat Capex Execution | ₹1,600 Cr project; mechanical completion Q4 FY26; full ramp FY27 | Medium | High | Phased capex; experienced EPC; ~70% complete as of Q1 FY26 |
| 3 | HF Feedstock Volatility | HF is a key feedstock; supply tightness during winter impacts costs | Medium | Medium | Long-term contracts; partial backward integration; chemical recycling |
| 4 | Customer Concentration | Top-10 customers ~52% of revenue; pharma innovator concentration | Medium | Medium | Active diversification; SME/agro channel build-out |
| 5 | AIM-Kigali HFC Phase-Down | India: 85% HFC reduction by 2047; revenue from HFCs in long-term decline | High | Medium | Transition to HFO; new generation refrigerants; counter-cyclical mix |
| 6 | China Capacity / Pricing Pressure | Chinese fluorination capacity overhang; pricing pressure in commoditised grades | High | Medium | Specialty differentiation; long-term contracts; "China+1" beneficiaries |
| 7 | Currency Volatility | ~58% exports; INR/USD volatility impacts realizations | High | Medium | Forward covers 60-90 days; natural hedge via imports |
| 8 | Working Capital Stress | Inventory 118 days FY25; could spike with capacity ramp | Medium | Medium | CCC improving; better forecasting; vendor financing |
| 9 | HFO Refrigerant Transition | Industry shifting from HFC to HFO/CO2 refrigerants; capex needed | Medium | Medium-High | R&D investment; pilot HFO capacity; customer co-development |
| 10 | Promoter Stake Dilution | Promoter stake 27.10%; further equity raise could dilute | Low | Low | No near-term equity plan; cash flows strong post-FY27 |
Regulatory & Environmental Risk Sub-Categories:
| Regulatory Domain | Framework | India Impact | Global Impact | NFIL Exposure |
|---|---|---|---|---|
| F-Gas / HFC Phase-Down | AIM-Kigali (India 2047) | Direct | F-Gas EU/USA | Medium |
| PFAS Regulation | EU REACH, US EPA | Indirect | High | High |
| REACH Registration | EU Regulation | Indirect | High | High |
| GMP Pharma Compliance | US FDA, EU EMA | Direct | Direct | High (Pharma) |
| TSCA (US Toxic Substances) | US EPA | Indirect | High | Medium |
| Hazardous Waste Mgmt. | India MoEFCC | Direct | n.a. | Medium |
| Water/Emissions | India CPCB/SPCB | Direct | n.a. | Medium |
| HFC Anti-Dumping (USA/EU) | Trade Defense | Direct | Direct | Medium |
Capex Project Risk Detail (Surat ₹1,600 Cr Phase):
| Project | Capex (₹ Cr) | Expected Commissioning | Payback (yrs) | Status | Risk |
|---|---|---|---|---|---|
| MP-2 (Multipurpose Plant 2) | ~400 | Commissioned Q1 FY25 | ~5 | Operational at 70% utilization | Low (Done) |
| MP-3 (Multipurpose Plant 3) | ~600 | Q4 FY26 (Mechanical) | ~6 | ~70% complete | Medium (Schedule) |
| HFC Capacity Expansion | ~250 | Q2 FY26 | ~4 | ~85% complete | Low |
| R&D Centre Expansion | ~150 | Q1 FY27 | n.a. (Strategic) | ~50% complete | Low |
| Dahej Phase 2 | ~200 | Q2 FY26 | ~5 | ~80% complete | Low |
| Total Surat Capex (FY25-27E) | ~1,600 | Phased FY25-27 | ~5-6 blended | On track | Medium |
§9. Investment Thesis
Five-Pillar Bull Case & Verdict
NAVINFLUOR is a multi-year compounder transitioning from a refrigerant-led cyclical to a specialty-driven franchise with differentiated fluorine chemistry and an emerging CRDMO platform. We initiate with a BUY rating and a 12-month fair value of ₹8,400 (17% upside). The five-pillar thesis is built on (1) specialty mix shift; (2) MP-2 ramp; (3) ME-GLIDE platform monetization; (4) capex peak passing; and (5) attractive entry point post the recent ~10% pullback from all-time highs.
Pillar 1: Specialty Mix Inflection Underway
| Indicator | FY22 | FY25 | FY28E | Implication |
|---|---|---|---|---|
| Specialty Revenue Mix % | ~38% | ~48% | ~62% | Premiumization |
| Pharma + Agro + Specialty | ~32% | ~40% | ~52% | Higher-multiple businesses |
| Refrigerants + Industrial | ~62% | ~52% | ~38% | Cyclicality reducing |
| Implied OPM % | 26% | 33% | 32% | Margins holding |
Pillar 2: MP-2 Ramp + MP-3 Visibility
| Plant | Status | FY26E Rev Contribution | FY27E Rev Contribution | Implied OPM Lift |
|---|---|---|---|---|
| MP-1 (Legacy) | Operational | ~₹2,400 Cr | ~₹2,500 Cr | Stable |
| MP-2 (New) | Ramping; 70% util. | ~₹1,000 Cr | ~₹1,300 Cr | +200-300 bps |
| MP-3 (New) | Commissioning Q4 FY26 | ~₹200 Cr | ~₹600 Cr | +150-200 bps |
| Dahej Phase 2 | Commissioning Q2 FY26 | ~₹250 Cr | ~₹400 Cr | +100 bps |
Pillar 3: ME-GLIDE CRDMO Platform
| Metric | FY25 | FY27E | FY30E | Implication |
|---|---|---|---|---|
| CRDMO Revenue (₹ Cr) | ~150 | ~450 | ~1,200 | 3-5x growth |
| Active Programs | ~10 | ~25 | ~50 | Customer additions |
| Commercial Molecules | 1 | ~6 | ~15 | Premium pricing |
| CRDMO OPM % | ~25% | ~38% | ~42% | Higher than blended |
| Implied EBITDA Contribution (FY30E) | n.a. | n.a. | ~₹500 Cr | ~15% of total EBITDA |
Pillar 4: Capex Peak Passing → Free Cash Flow Inflection
| Metric | FY23 | FY24 | FY25 | FY26E | FY27E |
|---|---|---|---|---|---|
| Capex (₹ Cr) | 1,094 | 511 | 1,235 | ~790 | ~950 |
| Capex/Sales % | 53% | 22% | 37% | ~20% | ~20% |
| Operating CF (₹ Cr) | 750 | 571 | 894 | ~1,100 | ~1,350 |
| Free Cash Flow (₹ Cr) | 72 | 4 | 404 | ~310 | ~400 |
| Net Debt/EBITDA (x) | 0.9 | 1.0 | 0.6 | ~0.5 | ~0.3 |
Pillar 5: Valuation Comfortable vs. Specialty Chemical Peers
| Company | P/E (FY27E) | EV/EBITDA (FY27E) | RoCE (FY27E) | Rev CAGR (FY25-27E) | EPS CAGR (FY25-27E) |
|---|---|---|---|---|---|
| NAVINFLUOR | 37x | 24x | ~22% | ~19% | ~22% |
| SRF | ~35x | ~20x | ~16% | ~14% | ~18% |
| AARTIIND | ~38x | ~19x | ~13% | ~14% | ~22% |
| DEEPAKNTR | ~30x | ~17x | ~14% | ~12% | ~17% |
| ATUL | ~28x | ~15x | ~12% | ~10% | ~13% |
| FINEORG | ~36x | ~24x | ~22% | ~12% | ~15% |
| Peer Average | ~33x | ~19x | ~15% | ~12% | ~17% |
| NFIL Premium / (Discount) to Peers | +12% | +26% | +47% | +58% | +29% |
Premium Justification:
| Justification Factor | Weight | Premium Justified | Comment |
|---|---|---|---|
| Higher Specialty Mix | High | +10-15% | 48% vs. peer 40% |
| ME-GLIDE Differentiation | Medium | +5-8% | Unique platform |
| Fluorine Chemistry Leadership | High | +8-12% | Pure-play advantage |
| RoCE / FCF Inflection | Medium | +5-7% | Visible re-rating |
| Export Orientation | Medium | +3-5% | 58% exports |
| Concentration Risk Discount | Low | -3-5% | Top-10 at 52% |
| Capex / Working Capital | Low | -2-3% | Near-term cash drag |
| Net Premium Justified | n.a. | +25-35% | Comfortable premium |
Bull / Base / Bear Scenarios:
| Scenario | Trigger | Implied Target (₹) | Probability | EPS FY27E (₹) |
|---|---|---|---|---|
| Bull | MP-2 at 90%+ util; ME-GLIDE wins 4+ commercial molecules; Surat capex ahead of schedule | 10,200 - 11,000 | 25% | ~220 |
| Base | MP-2 ramp 80-85%; 2 ME-GLIDE wins/year; capex on schedule | 8,200 - 8,800 | 50% | ~193 |
| Bear | MP-2 ramp <70%; capex delays; pricing pressure in HFCs | 5,800 - 6,500 | 25% | ~155 |
| Weighted | n.a. | 8,275 | 100% | ~190 |
12-Month Action Plan:
| Horizon | Catalyst | Action | Risk |
|---|---|---|---|
| Q1-Q2 FY26 | Q1 FY26 results (Aug 2025); Surat capex update; Q2 FY26 results (Nov 2025) | Accumulate on dips; track MP-2 utilization | Miss on Q1 FY26 margin |
| Q3-Q4 FY26 | Q3 FY26 results (Feb 2026); ME-GLIDE commercial wins; HFC pricing | Build core position; track Surat mechanical completion | Capex delay |
| H1 FY27 | MP-3 commissioning; FY27 guidance; first commercial ME-GLIDE molecule | Add aggressively; revise estimates up | Ramp slower than expected |
| H2 FY27-FY28 | Full ramp; FCF inflection; potential re-rating | Book partial profits at ₹9,500+; trail stop at ₹7,000 | Multiple compression |
Investor Action Recommendations:
| Investor Profile | Allocation Recommendation | Time Horizon | Entry Zone | Exit Zone |
|---|---|---|---|---|
| Long-term Compounder Seeker | 3-5% of equity portfolio | 3-5 years | ₹6,800 - 7,200 | ₹10,000 - 11,000 |
| Growth at Reasonable Price | 2-3% of portfolio | 2-3 years | ₹6,500 - 7,000 | ₹9,000 - 9,500 |
| Specialty Chemicals Thematic | 5-7% of chemicals allocation | 3-5 years | ₹6,800 - 7,200 | ₹10,000 - 12,000 |
| Tactical / Momentum | Avoid; wait for pullback | 6-12 months | ₹6,000 - 6,500 | ₹8,500 - 9,000 |
| Conservative / Income | Not recommended (low yield) | n.a. | n.a. | n.a. |
Final Investment Verdict:
| Parameter | Rating / Value | Comment |
|---|---|---|
| Overall Rating | BUY (3.7/5) | High-conviction specialty chemicals pick |
| 12-Month Target | ₹8,400 | 17% upside; 13% IRR inclusive of dividends |
| Bull Case Target | ₹10,500 | +45% upside |
| Bear Case Target | ₹5,800 | -19% downside |
| Risk-Reward Ratio | 1.6:1 (Base) | Favorable |
| Optimal Entry Zone | ₹6,800 - 7,200 | Current price in range |
| Stop-Loss Reference | ₹6,200 | ~14% below CMP |
| Time Horizon | 2-3 years | Multi-year compounding |
| Conviction Level | High | Best-in-class specialty chemicals franchise |
Key Catalysts & Milestones (Next 12-18 Months)
| Date / Period | Catalyst | Expected Impact |
|---|---|---|
| Aug 2025 | Q1 FY26 Results | Margin trajectory; MP-2 ramp update |
| Sep 2025 | Annual General Meeting | Capex guidance; new product pipeline |
| Nov 2025 | Q2 FY26 Results | MP-3 progress; specialty mix update |
| Q4 FY26 (Feb 2026) | MP-3 Mechanical Completion | Major capex milestone |
| Q4 FY26 | FY26 Full-Year Results | First full year of MP-2 contribution |
| Q1 FY27 (May-Jun 2026) | MP-3 Commissioning | Next growth leg |
| FY27 (Various) | ME-GLIDE Commercial Molecule Launches | CRDMO platform validation |
Summary Conclusion
Navin Fluorine International is a pre-eminent Indian specialty fluorine chemicals franchise that has successfully pivoted from a refrigerant-led cyclical to a specialty chemistry-led growth story with pharma, agro and CRDMO optionality. The Q4 FY25 results validated the thesis with revenue +30% YoY, OPM at a multi-year high of 34%, and PAT +82% YoY. The ₹1,600 Cr Surat capex will deliver MP-2 ramp benefits in FY26 and MP-3 commissioning in FY27, providing 2-3 years of high visibility on revenue and margin expansion. The ME-GLIDE platform is a differentiated, monetizable asset that few peers possess.
We rate NAVINFLUOR a BUY with a 12-month fair value of ₹8,400 (17% upside), supported by (1) DCF base case ₹8,400; (2) P/E 45x FY27E EPS ₹190 = ₹8,550; and (3) blended methodology ₹8,400. Key risks are regulatory (PFAS, HFC phase-down), capex execution, and feedstock volatility — all of which the company is actively mitigating. The current price offers a favorable risk-reward entry point for long-term investors seeking exposure to specialty chemicals' premium growth.
Bottom Line: NAVINFLUOR is a multi-year compounder with cyclical recovery tailwinds, capacity expansion, and specialty mix shift all converging — buy on dips, hold for 2-3 years, target ₹8,400 base / ₹10,500 bull.